Century Therapeutics, Inc.’s (NASDAQ:IPSC) price-to-sales (or “P/S”) ratio of 0.4x might make it look like a strong buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 10.2x and even P/S above 90x are quite common. However, the P/S might be quite low for a reason and it requires further investigation to determine if it’s justified.
View our latest analysis for Century Therapeutics
How Has Century Therapeutics Performed Recently?
Recent times have been advantageous for Century…
